

ASX Announcement

Dr John Byon appointed as Senior Vice President of Clinical Development

Sydney, Australia, 1 September 2023: Imugene Limited (ASX:IMU) (Company), a clinical stage immuno-oncology company, is pleased to announce the appointment of Dr John Byon as Senior Vice President of Clinical Development.

Dr Byon boasts an extensive background in the development of novel therapeutics for cancer patients. He has occupied several leadership roles at major biopharmaceutical companies, spearheading clinical development activities.

Most recently, Dr Byon served as Vice President of Clinical Development in Hematology and subsequently in acute myeloid leukemia (AML) at Fate Therapeutics. Here, he directed the clinical strategy for the Hematology portfolio, which comprises five assets in B-cell malignancies, AML, and Multiple Myeloma. He provided oversight for all ongoing Hematology trials as well as playing a pivotal role in restructuring the Clinical Development team.

Before his tenure at Fate, Dr Byon was the Senior Medical Director, Head of Clinical Science at Lyell Immunopharma. In this capacity, Dr Byon led clinical strategy development for portfolio assets, established the internal clinical science function, and represented clinical development in joint collaborations.

Additionally, Dr Byon served as Senior Medical Director at Juno Therapeutics, where as the Global Clinical Development Lead he was instrumental in the clinical development of orvacabtagene autoleucel (orva-cel/JCARH125) for relapsed/refractory multiple myeloma and other novel CAR T-cell targets.



He also assumed various Medical Director roles over a four-year span at Genentech, focused largely on managing clinical development activities for Tecentriq® (Atezolizumab) in various hematological malignancies. During this period, he conceptualized new clinical trials and represented the company at global advisory board meetings.

Dr Byon holds both a Doctor of Medicine and a Doctor of Philosophy from Tulane University. Beyond his corporate experience, Dr Byon has contributed to multiple academic publications in the hematology and oncology spaces.

Imugene CEO and Managing Director Leslie Chong said: "There is an excellent correlation with Dr Byon's experience and our portfolio of assets at Imugene, making him an outstanding fit for the Company. We look forward to him bringing his leadership and new perspectives into the clinical development team."

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter and Instagram @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited



About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.